glp-1 weight loss research The revolution: What UAB researchers are discovering about how these drugs work Changes in weight with GLP-1

In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that it helped people lower their weight by an average of 12% after 72 weeks.

This systematic review evaluates preclinical and clinical evidence on glucagon-like peptide-1 receptor agonists as potential treatments for substance use disorders

In this episode, we explore the use of GLP-1 therapy for weight management beyond diabetes, including who may benefit and who should avoid it.

We previously reported that the most abundant member of a specific protein complex to bind across the presumed causal variant at this locus, rs7903146, was poly [ADP-ribose] polymerase type 1 (PARP-1)

GLP-1 payment processing doesn't have to be an opaque, confusing subject

Diabetes GLP-1s perform better but still leak demand: Diabetes-indicated GLP-1s show higher retention (24% at one year) and face fewer access hurdles due to broader coverage and disease framing, yet 76% of demand remains unmet